Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
US-2022265699-A1 · Aug 25, 2022 · US
Cell protective methods and compositions
US11633424B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11633424-B2 |
| Application number | US-201917254145-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2019 |
| Priority date | Jun 20, 2018 |
| Publication date | Apr 25, 2023 |
| Grant date | Apr 25, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating histone toxicity in a subject, the method comprising: providing a subject in need of histone toxicity treatment; and administering to the subject a chondroitin sulfate (CS) compound, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof, and wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof, and wherein the histone toxicity in the subject is treated. 2. The method of claim 1 , wherein the subject is suffering from sepsis. 3. The method of claim 1 , wherein the subject is a human subject. 4. The method of claim 1 , wherein the chondroitin sulfate compound comprises one or more of the following structures: wherein R is selected from the group consisting of —H, alkyl, substituted alkyl, aryl, and substituted aryl, wherein n is 1, 2, 3, 4, 5, 6, 7 or 8. 5. The method of claim 1 , wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition. 6. The method of claim 1 , wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS. 7. A method of treating sepsis in a subject, the method comprising: providing a subject in need of sepsis treatment; and administering to the subject a chondroitin sulfate compound, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof, and wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof wherein the sepsis in the subject is treated. 8. The method of claim 7 , wherein the subject is a human subject. 9. The method of claim 7 , wherein the chondroitin sulfate compound comprises one or more of the following structures: wherein R is selected from the group consisting of —H, alkyl, substituted alkyl, aryl, and substituted aryl, wherein n is 1, 2, 3, 4, 5, 6, 7 or 8. 10. The method of claim 7 , wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition. 11. The method of claim 7 , wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS. 12. The method of claim 4 , wherein the alkyl is —CH 3 or —CH 2 CH 3 or the substituted aryl is a p-nitrophenyl group. 13. The method of claim 9 , wherein the alkyl is —CH 3 or —CH 2 CH 3 or the substituted aryl is a p-nitrophenyl group.
Assignees
Inventors
Classifications
- A61K31/737Primary
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence) · CPC title
Antibacterial agents · CPC title
Antidotes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11633424B2 cover?
- Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the…
- Who is the assignee on this patent?
- Univ North Carolina Chapel Hill
- What technology area does this patent fall under?
- Primary CPC classification A61K31/737. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).